Research Area
|
Description
|
Infection |
Biological Activity
|
Description
|
BTZ043 racemate is a decaprenylphosphoryl-β-D-ribose 2’-epimerase inhibitor acting as a new antimycobacterial agent that kill Mycobacterium tuberculosis. |
Targets
|
Decaprenylphosphoryl-β-D-ribose 2’-epim |
|
|
|
|
|
IC50 |
|
|
|
|
|
|
In Vitro
|
By targeting decaprenylphosphoryl-β-D-ribose 2’-epimerase, BTZ043 abolishes the formation of decaprenylphosphoryl arabinose, leading to cell lysis and death of Mycobacterium tuberculosis. BTZ043 displays similar activity against all clinical isolates of M. tuberculosis, including multidrug-resistant and extensively drug-resistant strains. BTZ043 displays significant activity against M. tuberculosis H37Rv and Mycobacterium smegmatis with MIC of 1 ng/mL (2.3 nM) and 4 ng/mL (9.2 nM), respectively, which is more potent than those of the existing tuberculosis (TB) drugs isoniazid (INH) and ethambutol (EMB) with MIC of 0.02-0.2 μg/mL and 1-5 μg/mL, respectively. BTZ043 is less effective in two different model systems (auxotrophy and starvation) involving metabolically inert M. tuberculosis, indicating that BTZ043 blocks a step in active metabolism similar to isoniazid (INH). BTZ043 treatment in M. smegmatis cells decreases the growth rate rapidly followed by a swelling of the poles and lysis of the cells after a few hours, which is similar but delayed in M. tuberculosis. [1] BTZ043 (1/4 MIC 0.375 ng/mL) in combination with TMC207 (1/4 MIC 20 ng/mL) has a stronger cidal effect on M. tuberculosis but not BTZ-resistant M. tuberculosis mutant than TMC207 alone at a concentration of 80 ng/mL. [2] |
In Vivo
|
In a mouse model of chronic tuberculosis, administration of BTZ043 at 37.5 mg/kg or 300 mg/kg for 4 weeks reduces the bacterial burden in the lungs and spleens by 1 and 2 logs, respectively. [1] |
Clinical Trials
|
|
Features
|
More active than EMB against M. tuberculosis. |
Protocol
|
Animal Study
[1]
|
Animal Models |
BALB/c mice infected with a low bacillary load (~200 CFU) of M. tuberculosis H37Rv via aerosol |
Formulation |
Formulated in carboxymethyl cellulose formulation (0.25%) |
Doses |
37.5 mg/kg, or 300 mg/kg |
Administration |
Oral gavage once daily |
|